Brevan Howard Capital Management »

Revance Therapeutics shares owned by Brevan Howard Capital Management

Quarter-by-quarter ownership of Revance Therapeutics (RVNC) shares owned by Brevan Howard Capital Management from 13F filings

Historical chart of Brevan Howard Capital Management investment in Revance Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Revance Therapeutics held by Brevan Howard Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Revance Therapeutics by Brevan Howard Capital Management

Quarter filed Position value Share count Share price at filing
2024-09-30 $2.7M 523k 5.19
2024-06-30 $101k 39k 2.57
2023-12-31 $238k 27k 8.79

More positions owned by Brevan Howard Capital Management

Ishares Msci Emerging Mkt In Msci Emg Mkt Etf (EEM)
Financial Select Sector Spdr Financial Call Option (XLF)
Ishares Ftse/xinhua China 25 China Lg-cap Etf Call Option (FXI)
Invesco QQQ Trust Series 1 Nasdaq100 BB:QQQ Unit Ser 1 (QQQ)
Ishares Iboxx H/y Corp Bond Iboxx Hi Yd Etf Call Option (HYG)
Industrial Select Sect Spdr Indl Call Option (XLI)
Consumer Staples Spdr Sbi Cons Stpls Call Option (XLP)
Health Care Select Secto Sbi Heathcare Call Option (XLV)
Ishares Russell 2000 Etf Russell 2000 Etf (IWM)
Spdr S&p Biotech Etf S&p Biotech (XBI)
KraneShares CSI China Internet ETF Csi Chi Internet Call Option (KWEB)
Energy Select Sector Spdr Energy Call Option (XLE)
Alibaba Group Holding Sponsored Ads (BABA)
Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)

View all positions for Brevan Howard Capital Management

Top funds holding Revance Therapeutics

BlackRock
BlackRock
Vanguard Group
Franklin Resources
Alpine Associates Management
Magnetar Financial
Tang Capital Management
Geode Capital Management
State Street Corporation
LMR Partners
D. E. Shaw & Co
Omni Event Management
Palo Alto Investors
CNH Partners
Gabelli Funds

View all funds holding Revance Therapeutics